Dr. Craig Kessler

Hematology
3800 Reservoir Rd Nw, 
Washington, DC 
3800 Reservoir Rd Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Craig Kessler is a Hematologist in Washington, Washington, D.c.. Dr. Kessler is rated as an Experienced provider by MediFind in the treatment of Drug-Induced Thrombocytopenia. His top areas of expertise are Blood Clots, Hemophilia A, Acquired Hemophilia, Bone Marrow Aspiration, and Splenectomy.

His clinical research consists of co-authoring 151 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in DC
Hospital Affiliations
Medstar Georgetown University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

MGMC LLC
3800 Reservoir Rd Nw, Washington, DC 20007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Enrollment Status: Completed
Publish Date: June 16, 2022
Intervention Type: Drug
Study Drugs: Itacitinib, Ruxolitinib
Study Phase: Phase 2
Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)
Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)
Enrollment Status: Completed
Publish Date: September 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
Research Tissue Bank
Research Tissue Bank
Enrollment Status: Completed
Publish Date: July 05, 2019
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Enrollment Status: Completed
Publish Date: December 13, 2018
Molecular Biology of Familial Myeloproliferative Disorders
Molecular Biology of Familial Myeloproliferative Disorders
Enrollment Status: Completed
Publish Date: September 05, 2017
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Enrollment Status: Completed
Publish Date: January 11, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

151 Total Publications

Correction: A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A.
Correction: A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A.
Journal: Genes and immunity
Published: September 25, 2025
Similar Doctors
Advanced in Drug-Induced Thrombocytopenia
Dr. Vinni Juneja
Hematology Oncology | Hematology | Oncology
Advanced in Drug-Induced Thrombocytopenia
Dr. Vinni Juneja
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

11886 Healing Way, 
Silver Spring, MD 
 (11.5 miles away)
301-933-3216
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Vinni Juneja is a Hematologist Oncology specialist and a Hematologist in Silver Spring, Maryland. Dr. Juneja is rated as a Distinguished provider by MediFind in the treatment of Drug-Induced Thrombocytopenia. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Thrombocytopenia, and Paget Disease of the Breast. Dr. Juneja is currently accepting new patients.

Advanced in Drug-Induced Thrombocytopenia
Dr. Jeanine L. Werner
Hematology Oncology | Hematology | Oncology
Advanced in Drug-Induced Thrombocytopenia
Dr. Jeanine L. Werner
Hematology Oncology | Hematology | Oncology

Maryland Oncology Hematology PA

10710 Charter Dr, Suite G020, 
Columbia, MD 
 (23.3 miles away)
410-964-2218
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeanine Werner is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Werner is rated as a Distinguished provider by MediFind in the treatment of Drug-Induced Thrombocytopenia. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Virilizing Ovarian Tumor. Dr. Werner is currently accepting new patients.

Advanced in Drug-Induced Thrombocytopenia
Dr. Yong P. Tang
Hematology Oncology | Hematology | Oncology
Advanced in Drug-Induced Thrombocytopenia
Dr. Yong P. Tang
Hematology Oncology | Hematology | Oncology
1185 Imperial Dr, Suite 103, 
Hagerstown, MD 
 (60.2 miles away)
301-797-8279
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients

Yong Tang is a Hematologist Oncology specialist and a Hematologist in Hagerstown, Maryland. Dr. Tang is rated as a Distinguished provider by MediFind in the treatment of Drug-Induced Thrombocytopenia. His top areas of expertise are Childhood Iron Deficiency Anemia, Anemia, Pulmonary Embolism, Vitrectomy, and Osteotomy. Dr. Tang is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kessler's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 10 Advanced Conditions
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile